Visit Summit: Booth #204
Barcelona, Spain
Saturday September 6, 2025
Satellite CME Symposium Sponsored by Summit Therapeutics
Session Time: 3:00 p.m. – 4:00 p.m. CEST (9:00 a.m. – 10:00 a.m. ET)
- Session: A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs
Sunday September 7, 2025
Presidential Symposium Oral Presentation
Session Time: 8:15 a.m. – 10:30 a.m. CEST (2:15 a.m. – 4:30 a.m. ET)
- Session: Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
- Location: PL02 Presidential Symposium 1
- Presenter: Jonathan W. Goldman, M.D.
P1.11. Metastatic Non-small Cell Lung Cancer – Immunotherapy
Poster Session Time: 10:30 a.m. – 12:00 p.m. CEST (4:30 a.m. – 6:00 a.m. ET)
- P1.11.65. Ivonescimab vs. Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor PD-L1 Expression Level
Presenter: Dr. Lei Wang
- P1.11.83. Ivonescimab vs. Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology
Presenter: Dr. Anwen Xiong